Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib + Cetuximab + Irinotecan in mCRC
NCT01075048Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of tivantinib in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-Free Survival at 80 weeks. Started Jan 2010; status: completed.
02
Drugs
tivantinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01075048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01075048.